Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyric Acid Effects Via the Gut-Brain

Launched by UNIVERSIDAD DE ALMERIA · Jan 21, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating whether a substance called tributyrin can help people with mild Alzheimer's disease (AD) by potentially improving their thinking and memory skills. The researchers want to find out if tributyrin can also reduce inflammation in the body and support gut health, as gut health is believed to play a role in brain function. Participants will take either tributyrin or a placebo (a non-active pill that looks the same) every day for 12 weeks. Throughout the trial, they will undergo tests to measure their cognitive function, check certain blood markers related to brain health, and assess their gut health.

To be eligible for this trial, individuals must have been diagnosed with mild Alzheimer's within the past year and agree to participate voluntarily. They should not be involved in other clinical trials or have other serious health issues that could affect the study's results. Participants will have the opportunity to contribute to important research that may help improve treatments for Alzheimer's disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • individuals diagnosed with mild AD within the past year (ICD-10: F00.1).
• • voluntary consent to participate in the study in accordance with the Declaration of Helsinki.
• • not currently enrolled in any other clinical trial that could confound the results.
• Exclusion Criteria:
• • individuals with other potential causes of dementia, such as a history of severe traumatic brain injury, brain tumours, epilepsy, or central nervous system infections.
• • individuals involved in an intervention that interferes with the trial (immunosuppressive drugs, steroids, antibiotics, or received chemotherapy in the month prior to the start of the intervention).
• • individuals with gastrointestinal disorders.